Open Access
J Extra Corpor Technol
Volume 38, Number 1, March 2006
Page(s) 52 - 56
Published online 15 March 2006
  1. Merry A, Raudkivi P, Middleton N, et al. Bivalirudin versus heparin and protamine in off pump coronary bypass surgery. Ann Thorac Surg. 2004;77:925–31. [CrossRef] [Google Scholar]
  2. Gibbon JHJ. The development of the heart-lung apparatus. Am J Surg. 1978;135:608–19. [CrossRef] [Google Scholar]
  3. Nunley RM, Lachiewicz PF. Mortality after total hip and knee arthroplasty in a medium-volume university practice. Journal of Arthroplasty. 2003;18:278–85. [CrossRef] [Google Scholar]
  4. Charlesworth DC, Likosky DS, Marrin CA, et al. Development and validation of a prediction model for strokes after coronary artery bypass grafting. Ann Thorac Surg. 2003;76:436–43. [CrossRef] [Google Scholar]
  5. Engoren MC, Habib RH, Zacharias A, et al. Effect of blood transfusion on long-term survival after cardiac operation. Ann Thorac Surg. 2002;74:1180–6. [CrossRef] [Google Scholar]
  6. Spiess BD. Blood transfusion: the silent epidemic. Ann Thorac Surg. 2001;72:S1832–7. [CrossRef] [Google Scholar]
  7. Spiess BD. Heparin: beyond an anticoagulant, The relationship between coagulation, inflammation, and endothelium. Edited by Spiess BD. Baltimore, 2000, pp. 169–90. [Google Scholar]
  8. Bauer TL, Arepally G, Konkle BA, et al. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation. 1997;95:1242–6. [CrossRef] [PubMed] [Google Scholar]
  9. Weitz JI, Crowther M. Direct thrombin inhibitors. Thrombosis Research. 2002;106:V275–84. [CrossRef] [PubMed] [Google Scholar]
  10. Spiess BD. Transfusion and outcome in heart surgery. Ann Thorac Surg. 2002;74:986–7. [CrossRef] [Google Scholar]
  11. Williams RT, Damaraju LV, Mascelli MA, et al. Anti-platelet factor 4/heparin antibodies: an independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes. Circulation. 2003;107:2307–12. [CrossRef] [PubMed] [Google Scholar]
  12. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330–5. [CrossRef] [PubMed] [Google Scholar]
  13. Pouplard C, May MA, Iochmann S, et al. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation. 1999;99:2530–6. [CrossRef] [PubMed] [Google Scholar]
  14. Mattioli AV, Bonetti L, Sternieri S, Mattioli G. Heparin-induced thrombocytopenia in patients treated with unfractionated heparin: prevalence of thrombosis in a 1 year follow-up. Ital Heart J. 2000;1:39–42. [Google Scholar]
  15. Simoons ML. GUSTO IV-ACS Investigators: Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet. 2001;357:1915–24. [CrossRef] [PubMed] [Google Scholar]
  16. Newman PM, Swanson RL, Chong BH. Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid. Thrombosis & Haemostasis. 1998;80:292–7. [CrossRef] [PubMed] [Google Scholar]
  17. Bates SM, Weitz JI. Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. Am J Cardiol. 1998;82:12P–8P. [CrossRef] [Google Scholar]
  18. Butterworth J, Lin YA, Prielipp RC, et al. Rapid disappearance of protamine in adults undergoing cardiac operation with cardiopulmonary bypass. Ann Thorac Surg. 2002;74:1589–95. [CrossRef] [Google Scholar]
  19. Kimmel SE, Sekeres M, Berlin JA, Ellison N. Mortality and adverse events after protamine administration in patients undergoing cardiopulmonary bypass. Anesth Analg. 2002;94:1402–8. [CrossRef] [PubMed] [Google Scholar]
  20. Physician’s Desk Reference. Protamine, 2000. [Google Scholar]
  21. Frederiksen JW. Cardiopulmonary bypass in humans: bypassing unfractionated heparin. Ann Thorac Surg. 2000;70:1434–43. [CrossRef] [Google Scholar]
  22. Weitz JI. Low-molecular-weight heparins. New England Journal of Medicine. 1997;337:688–98. [CrossRef] [PubMed] [Google Scholar]
  23. Massonnet-Castel S, Pelissier E, Bara L, et al. Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation. Haemostasis. 1986;16:139–46. [PubMed] [Google Scholar]
  24. Newman PM, Chong BH. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood. 2000;96:182–7. [CrossRef] [PubMed] [Google Scholar]
  25. Doherty DC, Ortel TL, de Bruijn N, Greenberg CS, Van Trigt P3rd. “Heparin-free” cardiopulmonary bypass: first reported use of heparinoid (Org 10172) to provide anticoagulation for cardiopulmonary bypass. Anesthesiology. 1990;73:562–5. [CrossRef] [PubMed] [Google Scholar]
  26. Illig KA, Ouriel K. Ancrod: understanding the agent. Seminars in Vascular Surgery. 1996;9:303–14. [PubMed] [Google Scholar]
  27. Brieger DB, Mak KH, Kottke-Marchant K, Topol EJ. Heparin-induced thrombocytopenia. Journal of the American College of Cardiology. 1998;31:1449–59. [CrossRef] [PubMed] [Google Scholar]
  28. Walls JT, Curtis JJ, Silver D, et al. Heparin-induced thrombocytopenia in open heart surgical patients: sequelae of late recognition. Ann Thorac Surg. 1992;53:787–91. [CrossRef] [Google Scholar]
  29. Laster J, Elfrink R, Silver D. Reexposure to heparin of patients with heparin-associated antibodies. J Vasc Surg. 1989;9:677–82. [CrossRef] [Google Scholar]
  30. Koster A, Kukucka M, Bach F, et al. Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban. Anesthesiology. 2001;94:245–51. [CrossRef] [PubMed] [Google Scholar]
  31. Koster A, Meyer O, Fischer T, et al. One-year experience with the platelet glycoprotein IIb/IIIa antagonist tirofiban and heparin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II. Journal of Thoracic & Cardiovascular Surgery. 2001;122:254–5. [Google Scholar]
  32. Potzsch B, Klovekorn WP, Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. New England Journal of Medicine. 2000;343:515. [CrossRef] [PubMed] [Google Scholar]
  33. Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with Heparin-Induced Thrombocytopenia. Ciruclation. 2003;108:2062–5. [CrossRef] [PubMed] [Google Scholar]
  34. Nowak G, Bucha E. Prothrombin conversion intermediate effectively neutralizes toxic levels of hirudin. Thrombosis Research. 1995;80:317–25. [CrossRef] [PubMed] [Google Scholar]
  35. Koster A, Kuppe H, Hetzer R, et al. Emergent cardiopulmonary bypass in five patients with heparin-induced thrombocytopenia type II employing recombinant hirudin. Anesthesiology. 1998;89:777–80. [CrossRef] [PubMed] [Google Scholar]
  36. Fischer BE, Schlokat U, Himmelspach M, Dorner F. Binding of hirudin to meizothrombin. Protein Engineering. 1998;11:715–21. [CrossRef] [Google Scholar]
  37. Koster A, Chew D, Grundel M, et al. Bivalirudin monitored with the ecarin clotting time for anticoagulation during cardiopulmonary bypass. Anesthesia & Analgesia. 2003;96:383–6. [Google Scholar]
  38. Hursting MJ, Alford KL, Becker JC, et al. Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor. Seminars in Thrombosis & Hemostasis. 1997;23:503–16. [CrossRef] [PubMed] [Google Scholar]
  39. Lubenow N, Selleng S, Wollert HG, et al. : Heparin-induced thrombocytopenia and cardiopulmonary bypass: perioperative argatroban use. Ann Thorac Surg 2003;75:577–9. [CrossRef] [PubMed] [Google Scholar]
  40. Edwards JT, Hamby JK, Worrall NK. Successful use of Argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiac surgical patient. Ann Thorac Surg. 2003;75:1622–4. [CrossRef] [Google Scholar]
  41. Furukawa K, Ohteki H, Hirahara K, Narita Y, Koga S. The use of argatroban as an anticoagulant for cardiopulmonary bypass in cardiac operations. Journal of Thoracic & Cardiovascular Surgery. 2001;122:1255–6. [CrossRef] [Google Scholar]
  42. Robson R, White H, Aylward P, Frampton C. Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender. Clinical Pharmacology & Therapeutics. 2002;71:433–9. [CrossRef] [PubMed] [Google Scholar]
  43. Fox I, Dawson A, Loynds P, et al. Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans. Thrombosis & Haemostasis. 1993;69:157–63. [CrossRef] [PubMed] [Google Scholar]
  44. White H. Hirulog, Early Reperfusion or Occlusion -2 Trial I: Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet. 2001;358:1855–63. [Google Scholar]
  45. Fuchs J, Cannon CP. Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial. Circulation. 1995;92:727–33. [CrossRef] [PubMed] [Google Scholar]
  46. Antman EM, McCabe CH, Braunwald E. Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial. The Thrombolysis in Myocardial Infarction. American Heart Journal. 2002;143:229–34. [CrossRef] [PubMed] [Google Scholar]
  47. Potzsch B, Madlener K, Seelig C, et al. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass-assessment of the whole blood ecarin clotting time. Thrombosis & Haemostasis. 1997;77:920–5. [Google Scholar]
  48. Despotis GJ, Hogue CW, Saleem R, et al. The relationship between hirudin and activated clotting time: implications for patients with heparin-induced thrombocytopenia undergoing cardiac surgery. Anesthesia & Analgesia. 2001;93:28–32. [CrossRef] [PubMed] [Google Scholar]
  49. Potzsch B, Hund S, Madlener K, Unkrig C, Muller-Berghaus G. Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay. Thrombosis Research. 1997;86:373–83. [CrossRef] [PubMed] [Google Scholar]
  50. Koster A, Despotis G, Gruendel M, et al. The plasma supplemented modified activated clotting time for monitoring of heparinization during cardiopulmonary bypass: a pilot investigation. Anesthesia & Analgesia. 2002;95:26–30. [CrossRef] [PubMed] [Google Scholar]
  51. Koster A, Kuppe H, Crystal GJ, Mertzlufft F. Cardiovascular surgery without cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II using anticoagulation with recombinant hirudin. Anesthesia & Analgesia. 2000;90:292–8. [CrossRef] [PubMed] [Google Scholar]
  52. Cho L, Kottke-Marchant K, Lincoff AM, et al. Correlation of point-of-care ecarin clotting time versus activated clotting time with bivalirudin concentrations. American Journal of Cardiology. 2003;91:1110–3. [CrossRef] [Google Scholar]
  53. Demir M, Iqbal O, Untch B, et al. Ecarin clotting time is sensitive to heparinoids: comparison of two different techniques. Clinical & Applied Thrombosis/Hemostasis. 2001;7:38–43. [CrossRef] [PubMed] [Google Scholar]
  54. Pivalizza EG. Monitoring of hirudin therapy with the Thrombelastograph. Journal of Clinical Anesthesia. 2002;14:456–8. [CrossRef] [PubMed] [Google Scholar]
  55. Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. NEJM. 1995;333:764–9. [CrossRef] [PubMed] [Google Scholar]
  56. Topol EJ, Bonan R, Jewitt D, et al. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation. 1993;87:1622–9. [CrossRef] [PubMed] [Google Scholar]
  57. Mariani MA, Gu YJ, Boonstra PW, et al. Procoagulant activity after off-pump coronary operation: is the current anticoagulation adequate? Ann Thorac Surg. 1999;67:1370–5. [CrossRef] [Google Scholar]
  58. The Direct Thrombin Inhibitor Trialists’ Collaborative G. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients’ data. [comment]. Lancet. 2002;359:294–302. [CrossRef] [PubMed] [Google Scholar]
  59. Kong DF, Topol EJ, Bittl JA, et al. Clinical outcomes of bivalirudin for ischemic heart disease. Circulation. 1999;100:2049–53. [CrossRef] [PubMed] [Google Scholar]
  60. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289:853–63. [CrossRef] [PubMed] [Google Scholar]
  61. Puskas JD, Thourani VH, Marshall JJ, et al. Clinical outcomes, angiographic patency, and resource utilization in 200 consecutive off-pump coronary bypass patients. Ann Thorac Surg. 2001;71:1477–83; discussion 1483-4. [CrossRef] [Google Scholar]
  62. Angelini GD, Taylor FC, Reeves BC, Ascione R. Early and midterm outcome after off-pump and on-pump surgery in Beating Heart Against Cardioplegic Arrest Studies (BHACAS 1 and 2): a pooled analysis of two randomised controlled trials. Lancet. 2002;359:1194–9. [CrossRef] [PubMed] [Google Scholar]
  63. Zehr KJ, Handa N, Bonilla LF, Abel MD, Holmes DRJr. Pitfalls and results of immediate angiography after off-pump coronary artery bypass grafting. Heart Surg Forum. 2000;3:293–9. [Google Scholar]
  64. Kim KB, Lim C, Lee C, et al. Off-pump coronary artery bypass may decrease the patency of saphenous vein grafts. Ann Thorac Surg. 2001;72:S1033–7. [CrossRef] [Google Scholar]
  65. Spiess BD, DeAnda A, McCarthy A, et al. Off pump CABG in a patient with HITT anticoagulated with bivalirudin: a case report. Anesth Analg. 2002;93:SCA70. [Google Scholar]
  66. Davis Z, Anderson R, Short D, Garber D, Valgiusti A. Favorable outcome with bivalirudin anticoagulation during cardiopulmonary bypass. Ann Thorac Surg. 2003;75:264–5. [CrossRef] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.